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Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large 
international cohort.  
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Abstract  
NIPA1 (non-imprinted in Prader-Willi/Angelman syndrome 1) mutations are known to cause 
Hereditary Spastic Paraplegia type 6, a neurodegenerative disease that phenotypically 
overlaps to some extent with Amyotrophic Lateral Sclerosis. Previously, a genome-wide 
screen for copy number variants found an association with rare deletions in NIPA1 and ALS, 
and subsequent genetic analyses revealed that long (or expanded) polyalanine repeats in 
NIPA1 convey increased ALS susceptibility. We set out to perform a large-scale replication 
study to further investigate the role of NIPA1 polyalanine expansions with ALS, in which we 
characterized NIPA1 repeat size in an independent international cohort of 3,955 ALS 
patients and 2,276 unaffected controls and combined our results with previous reports. 
Meta-analysis on a total of 6,245 ALS patients and 5,051 controls showed an overall 
increased risk of ALS in those with expanded (>8) GCG-repeat length (odds ratio = 1.50, P = 
3.8x10-5). Together with previous reports, these findings provide evidence for an association 
of an expanded polyalanine repeat in NIPA1 and ALS.  
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1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder 
characterized by the loss of both upper and lower motor neurons leading to progressive 
weakness, spasticity and ultimately respiratory failure (Hardiman et al., 2011; van Es et al., 
2017). The complex genetic architecture of ALS is characterized by 5-15% of patients with a 
positive family history, where it is assumed that there is a single causal mutation (Andersen 
and Al-Chalabi, 2011). However, even in the majority of seemingly sporadic patients a large 
genetic contribution is expected and causal mutations have been reported despite a 
negative family history (Al-Chalabi et al., 2016; McLaughlin et al., 2015). To date, mutations 
in more than 20 different genes have been implicated in ALS, one of the most prominent 
being an intronic repeat expansion in C9orf72 (Al-Chalabi et al., 2016).  
In addition to C9orf72, repeat expansions in other genes have been reported in ALS, 
including ATXN2 and NIPA1 (Blauw et al., 2012; Elden et al., 2010). NIPA1 (non-imprinted 
in Prader-Willi/Angelman syndrome 1) mutations are known to cause Hereditary Spastic 
Paraplegia type 6, a neurodegenerative disease characterized by slowly progressive upper 
motor neuron signs (predominantly in the lower limbs) and is a condition that to some extent 
has phenotypic overlap with ALS (Rainier et al., 2003). Interestingly, a genome-wide screen 
for copy number variants found an association with rare deletions in NIPA1 and ALS and 
subsequent genetic analyses revealed that long (or expanded) polyalanine repeats in NIPA1 
confer increased disease susceptibility (Blauw et al., 2012; 2010). In the majority of people 
(98%) the 5’-end of NIPA1 (NCBI: NM_144599.4) encodes for a stretch of 12 or 13 alanine 
residues of which 7 or 8 are encoded by a (GCG)n trinucleotide repeat (TNR), although both 
shorter and longer GCG stretches have been reported in non-affected individuals (Chai et 
al., 2003). In this previous study, an analysis of an international cohort of 2,292 ALS patients 
and 2,777 controls showed that “long” repeats (>8) in NIPA1 were enriched in ALS cases 
compared to controls (5.5% vs. 3.6%; OR 1.71; P = 1.6 x 10-4) (Blauw et al., 2012).  
Although interesting and potentially relevant, only a small fraction of initially positive 
results from candidate gene studies (such as that performed on NIPA1) replicated 
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consistently (Hirschhorn et al., 2002). Therefore, additional steps, such as replication of the 
findings and imposing a proper significance threshold (such as exome or genome-wide 
significance), are required to make any claims of causality (MacArthur et al., 2014). 
We therefore set out to perform a large-scale replication study to further investigate the 
role of NIPA1 polyalanine expansions with ALS, in which we characterized NIPA1 repeat 
size in a large international cohort of ALS patients and unaffected controls and then meta-
analyze our results with previous reports. 
 
2. Material and Methods 
 
2.1 Subjects 
All participants gave written informed consent and approval was obtained from the local, 
relevant ethical committees for medical research. Genotyping experiments were performed 
on 6,231 samples comprising 3,955 ALS patients and 2,276 healthy controls from 6 
populations. All patients were diagnosed according to the revised El Escorial criteria. Control 
subjects were from ongoing population-based studies on risk factors in ALS. All related 
individuals were excluded from further analysis. Baseline characteristics for available 
samples are provided in Supplementary Table 1. 
 
2.2 PCR, sequencing and genotyping 
Dutch samples obtained from 753 ALS and 603 unaffected individuals were analyzed 
using PCR according to protocols described previously and results were analyzed in a 
blinded and automated fashion with a call rate of 96.6% (Blauw, et al., 2012). Samples that 
failed genotyping, were additionally analyzed with Sanger sequencing to assess possible 
bias. An additional cohort of 767 unaffected controls and 764 ALS samples were genotyped 
using Sanger sequencing and automatically genotyped with a call rate of 99.1%. Primers: 5’-
GCCCCTCTTCCTGCTCCT-3’ (forward) and 5’-CGATGCCCTTCTTCTGTAGC -3’ (reverse). 
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A total of 847 samples were analyzed using both methods (PCR and Sanger), with manual 
review of discordant genotypes (n = 35, 4.1%).  
We analyzed NIPA1 repeat size in whole-genome sequencing (WGS) data of 3,344 
samples (2,438 cases and 906 controls) from the HiSeq X Sequencing platform, available to 
us through Project MinE (Project MinE ALS Sequencing Consortium, 2018), using the 
Illumina ExpansionHunter tool (Dolzhenko et al., 2017). There was a 691 sample overlap 
genotyped using both ExpansionHunter and Sanger sequencing, showing a 99% 
concordance (n = 684). Considering this 99% concordance between ExpansionHunter and 
Sanger results in the Dutch dataset, we did not perform additional validation experiments on 
the WGS samples and proceeded with the ExpansionHunter calls. C9orf72 status had been 
determined for 3,907 ALS samples from the PCR, Sanger and ExpansionHunter cohorts. 
Additionally, the presence of rare non-synonymous and loss-of-function variants in the 
established ALS-associated genes SOD1, FUS and TARDBP was known for 5,030 cases 
and controls from all cohorts as described previously (Dekker et al., 2016; Project MinE ALS 
Sequencing Consortium, 2018). 
 
2.3 Statistical analysis 
All statistical procedures were carried out in R 3.3.0 (http://www.r-project.org). For 
association analyses we applied a logistic regression analysis to all subgroups, the effect of 
the expanded (>8) versus non-expanded polyalanine repeat length on the disease status, 
adjusting for sex at birth, method of genotyping and country of origin. Samples with missing 
sex at birth status (n = 108, 1%) were imputed using multivariate multiple imputation with the 
‘mice’ 2.46.0 package.  
Subgroup effects were meta-analyzed using both fixed and random effects modelling 
using the ‘metafor’ 2.0 package. For the joint analysis on individual data, we used a 
generalized linear model (GLM) with fixed-effects covariates: sex, method of genotyping and 
country of origin. We additionally applied generalized linear mixed model (GLMM) on non-
imputed data to account for possible random effects.  
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The survival after onset and age at onset analyses were performed using multivariate 
Cox regression with sex at birth, site of onset, age at onset (for survival only) and C9orf72 
status as covariates.  
To assess whether the observed frequency of co-occurring genetic risk variants for ALS 
was in excess of what would be expected on the basis of chance, we used a method 
described previously by (Dekker et al., 2016). The expected frequency of co-occurring 
variants was calculated using the following formula: (the observed number of patients 
carrying a variant / the total number of patients) * (the observed number of controls carrying 
a variant / the total number of controls). This formula was used in order to take into account 
the higher frequency of just one variant in ALS patients (= frequency of variants in patients), 
multiplied by the chance probability of a second variant (= frequency of variants in controls). 
Then, a binomial test was performed to compare the observed frequency of co-occurring 
variants in ALS patients with the calculated expected frequency. 
We specified a formal null model for an increase in repeat expansion with consideration 
of repeat confounding variables such as the genomic frequency and repeat size. Previous 
studies have shown that there are a total of 878 genes in the genome that contain a coding 
trinucleotide repeat (TNR) with a repeat size of 6 repeats or greater, 90 of which contain a 
polyalanine tract (Kozlowski et al., 2010). We therefore set two thresholds for significance in 
this study; 1) a relatively loose threshold, in which we correct for the number of genes that 
contain a polyalanine tract of 6 or larger resulting in P = 0.05/90 = 5.6x10-4 and 2) a more 
conservative threshold, in which we correct for the total number of genes in the genome that 
contain a coding TNR with a size of 6 or larger which gives P = 0.05/878 = 5.7x10-5. 
 
3. Results 
 
3.1 Replication 
We first tried to replicate the initial findings in an independent Dutch cohort comprising 
1,517 ALS cases and 1,370 unaffected controls by genotyping the GCG repeat length in 
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NIPA1 using repeat PCR and/or Sanger sequencing. As was reported previously, we found 
the most frequent alleles to consist of either 7 or 8 (GCG)n repeats (25% and 72% 
respectively) (Figure 1). Our analysis showed a similar allele frequency difference of 
expanded or “long” alleles (repeat length of 9 or longer) between ALS (n = 85, 2.80%) and 
controls (n = 51, 1.86%). Both ALS and control subgroups had only one single case with a 
homozygous expansion, indicating a dominant model for further analysis. This resulted in 84 
individuals with ALS (5.54%) and 50 unaffected individuals (3.65%) as carriers of an 
expanded NIPA1 polyalanine repeat length. Logistic regression analysis, corrected for sex at 
birth and method of genotyping (PCR or Sanger), revealed an effect of expanded NIPA1 
repeat length on disease susceptibility (OR = 1.54, P = 0.018). 
 
3.2 Project MinE 
To further increase sample size and investigate cohorts other than the Dutch population, 
we then analyzed NIPA1 repeat expansion genotypes that were called using the Illumina 
ExpansionHunter tool in 2,438 independent ALS cases and 906 controls whole-genome 
sequenced (WGS) as part of the Project MinE ALS Sequencing Consortium (Project MinE 
ALS Sequencing Consortium, 2018). This multi-cohort WGS data showed a more equal 
distribution of expanded NIPA1 carriers in ALS (114/2,438, 4.67%) and controls (40/906, 
4.42%). A logistic regression analysis, corrected for country of origin and sex, showed no 
significant difference. 
 
3.3 Meta-analysis  
Finally, we sought to perform an analysis of all available NIPA1 polyalanine expansion 
data, combining our data with the original data published previously (Blauw et al., 2012). 
After exclusion of duplicate samples; individual level data was available for a total of 5,056 
samples (2,290 cases and 2,775 controls) in the discovery dataset published by Blauw et al. 
(2012). Our replication cohort (including results from PCR, Sanger and Expansion Hunter) 
comprised 3,955 cases and 2,276 controls. The final dataset included 6,245 ALS patients 
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and 5,051 controls, reaching a final number of 11,296 unique individuals. We combined this 
data in a fixed-effects meta-analysis and found an overall risk of expanded NIPA1 repeat 
length on ALS (odds ratio (OR) = 1.50, P = 3.8x10-5) (Figure 2). Since individual level data 
was available, we additionally performed a multivariate logistic regression analysis, using 
sex at birth, method of genotyping and country of origin as covariates in the pooled data, 
resulting in an equal effect and significance (OR = 1.48, P = 6.2x10-5). Other association 
models that account for random effects, such as random effect meta-analysis and a 
generalised linear mixed model gave similar results (data not shown). Repeating the 
analysis excluding the 322 C9orf72 repeat expansion carriers yielded a P value of 7.7x10-5 
for the fixed-effects meta-analysis (OR = 1.49, 95% confidence interval (CI) = 1.22-1.81) and 
a P value of 1.0x10-4 for the multivariate logistic regression analysis (OR = 1.47, 95% CI = 
1.21-1.78). Exclusion of an additional 171 samples (133 cases and 38 controls) carrying a 
non-synonymous or loss-of-function mutation in SOD1, FUS or TARDBP did not alter the 
results (fixed-effects meta-analysis P value = 7.5 x10-5, OR = 1.49, 95% CI = 1.22-1.81) 
(Supplementary Figure 1). 
 
3.4 Survival 
Clinical data and survival data was available for 1,954 out of 3955 ALS patients from the 
combined replication cohorts (Supplementary Table 2). After correction for sex, age at 
onset, bulbar site of onset and C9orf72 status, we used a Cox regression model in this 
mixed population to test if NIPA1 conferred any risk for shorter survival time; we found no 
evidence for such an effect (Hazard ratio (HR) = 1.16; 95% CI = 0.94-1.45; P = 0.16) 
(Supplementary Figure 2). Also, there was no significant association between NIPA1 
repeat length and age at onset in this replication cohort with correction for sex, site of onset 
and the presence of a C9orf72 expansion (Supplementary Figure 3).  
 
3.4 Co-occurrence with C9orf72 repeat expansion 
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Since a significant number of NIPA1 expansion carriers was reported in a subgroup of 
ALS patients that also carried a C9orf72 repeat expansion (Dekker et al., 2016), we 
evaluated this co-occurrence in 4,619 participants genotyped for both loci in all cohorts (n = 
712 for the discovery cohort; n = 3,907 for the combined replication cohorts).  
Although we did observe a higher than expected frequency of co-occurrence of the repeat 
expansions, our data did not robustly replicate the previously published finding (0.37% 
observed vs 0.26% expected; P = 0.06) (Supplementary Table 3). 
 
4. Discussion 
In this study, we included a large international cohort and additionally meta-analyzed the 
NIPA1 expansion genotypes in a total of 6,245 ALS patients and 5,051 controls. Given that 
we were able to replicate our previous results in an independent cohort and observed an 
increase in significance in the overall meta-analysis, our data adds to the evidence that 
expanded NIPA1 repeats are a risk factor for sporadic ALS. Mutations in NIPA1 were 
already known to cause Hereditary Spastic Paraplegia type 6, a neurodegenerative disease 
with motor-neuron involvement, whereas the 15q11.2 microdeletions are better known for 
low penetrant neurodevelopmental phenotypes, further adding to the complexity of the 
NIPA1 locus (Butler, 2017; Rainier et al., 2003). Interestingly, genetic pleiotropy between 
HSP and ALS appears to be more widespread, as recently it has been shown that mutations 
in different domains in KIF5A either cause HSP or ALS (Brenner et al., 2018; Nicolas et al., 
2018).  
After C9orf72 and ATXN2, NIPA1 is the third reported expanded genomic repeat motif 
associated with an increased risk for ALS. Its initial discovery in ALS by identification of copy 
number variants in the chromosome 15q11.2 locus containing NIPA1, was followed by 
further genetic screening in a large international cohort consisting of Belgian, Dutch, and 
German subjects (Chai et al., 2003). This subsequent study in 2,292 ALS patients and 2,777 
controls revealed that, although NIPA1 deletions and missense mutations were identified in 
ALS patients, it actually was an increase of the (GCG)n repeat motif in the 5’-end of NIPA1 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 11
that seemed to associate with ALS (OR = 1.71 with P = 1.6x10-4). Knowing that positive 
results derived from candidate gene studies often fail to replicate, we sought to replicate the 
NIPA1 finding in ALS, particularly given the complex genotypic and phenotypic architecture 
of the NIPA1 locus (Messaed and Rouleau, 2009). 
Our results showed a very similar effect of increased NIPA1 polyalanine expansions on 
ALS-susceptibility in a new Dutch cohort of 1,517 ALS cases and 1,370 unaffected controls 
tested via PCR or Sanger sequencing. Given the high concordance between Sanger/PCR 
results and the calls from the bioinformatic tool ExpansionHunter on WGS data, we were 
able to further increase the sample size of our study by including data from Project MinE 
(Shinchuk et al., 2005). This allowed us to additionally evaluate the role of NIPA1 repeat 
sizes in non-Dutch cohorts. The size of this cohort was similar in the number of cases 
compared to the original discovery cohort, but smaller in number of controls compared to 
that original cohort. Also, the Project MinE dataset is more heterogeneous compared to the 
original discovery cohort. This is a possible explanation as to why the overall NIPA1 signal 
was not replicated in the WGS data. However, we did find a similar direction and effect size 
in 4 out of the 6 WGS cohorts (Ireland, Spain, the United States of America and the United 
Kingdom).  
While empirical thresholds for genome-wide and exome-wide significance have been 
derived for studies assessing associations between phenotypes and single nucleotide 
variants, these thresholds are likely to be too stringent in the context of screening for coding 
repeat expansions, as the genome contains only ~900 genes with a coding TNR tract with a 
length of 6 or more, 90 of which code for a polyalanine tract (Messaed and Rouleau, 2009). 
We therefore set the significance threshold for associations with TNRs to be approximately 
P = 5.6x10-4, correcting for polyalanine only, or (more conservative) P = 5.7x10-5, correcting 
for all TNRs with a length of 6 repeats or more. The meta-analysis results are significant 
regardless of the threshold applied. Furthermore, exclusion of samples carrying a mutation 
in established ALS genes (C9orf72, SOD1, TARDBP and FUS) yielded somewhat lower P 
values (due to loss of power corresponding to lower number of included samples) with 
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similar magnitude of effect, further supporting the role of NIPA1 as independent risk factor 
for developing ALS.     
Although we did see a higher than expected number of ALS cases carrying both NIPA1 
and C9orf72 repeat expansions in this study (n = 17, P = 0.06), we did not robustly 
reproduce the co-occurrence of C9orf72 expansion carriers in the NIPA1 expanded cases 
described by Dekker et al. (2016). This might be attributed to the relatively small sample size 
in the original study (755 ALS patients), resulting in broad confidence intervals that overlap 
with our results (frequency = 0.004 [0.002-0.006] in the current study; frequency = 0.009 
[0.004-0.019] in Dekker et al. (2016). Alternatively, the co-occurrence might be relevant in 
some, but not all included populations. Additionally, we were unable to replicate the effect of 
NIPA1 expansions on ALS survival and age at onset (Blauw et al., 2012). These findings 
again reemphasize the necessity for replication and the importance of tracking clinical 
characteristics in large genetic databases. Currently, we were able to perform a survival 
analysis on just 50% of our replication set and further evaluation in a larger and complete 
dataset is therefore recommended.   
Interestingly, the increase in the NIPA1 repeat size seems to be limited to the addition of 
mostly two GCG repeats. However, this seemingly small addition might well have protein 
conformational effects as has been shown in-vitro; polyalanine stretches between 7 to 15 
alanines transition from a monomeric alpha helix to a predominant macromolecular beta 
sheet, which in turn may lead to stronger protein–protein interactions and aggregation 
(Blauw et al., 2010). Additionally, a patient with a mutation in NIPA1 suffering from a 
progressive motor neuron phenotype was shown to have TDP-43 inclusions, very similar to 
effects seen in ALS and ALS-FTD cases(Martinez-Lage et al., 2012). These findings might 
explain how alterations in NIPA1 could increase ALS risk. 
In conclusion, our data adds to the evidence for an association of NIPA1 expansions and 
ALS. Future investigations may provide further insights in the role of NIPA1 and polyalanine 
stretches in the development and possibly treatment of motor neuron disease. 
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Figure 1. NIPA1 polyalanine repeat length distribution. 
Proportion of total alleles grouped per NIPA1 polyalanine repeat size. Alleles displayed were 
observed multiple times in the Dutch replication cohort of 1517 individuals affected with ALS 
(blue) and 1370 unaffected controls (orange). 
 
 
Figure 2. NIPA1 polyalanine repeat expansion meta-analysis. 
Forest plot for the fixed-effect meta-analysis and joint analysis on individual level data of the 
effect of expanded NIPA1 polyalanine (>8 GCG repeats) on ALS risk with the initial 
discovery reports (Blauw, et al., 2012) and current replication using PCR, Sanger or whole 
genome sequencing (WGS) grouped per cohort/country of origin. Weights depending on 
number of participants. CI, confidence interval.  
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Highlights 
• We replicated the association of long PolyA-repeats in NIPA1 with ALS in an 
independent Dutch cohort. 
• A subsequent meta-analysis on 6,245 cases and 5,051 controls yielded P = 3.8x10-5 
with OR = 1.50. 
• NIPA1 repeat expansions are not associated with ALS age of onset or survival. 
• NIPA1 repeat expansions (>8 GCG-repeats) are a risk factor for sporadic ALS.  
